Bifunctional inhibitors of urokinase and metalloproteinase-9 for cancer treatment - in silico evaluation
Matrix metalloproteinase-9 (MMP-9), and urokinase plasminogen activator (uPA) overexpression or/and increased activity are considered causative elements for cancer invasion and metastasis. These enzymes are degrading the extracellular matrix (ECM) providing space for cancer progression and cancer ce...
Main Authors: | Shawn P. Brewer, Jerzy Jankun |
---|---|
Format: | Article |
Language: | English |
Published: |
The University of Toledo
2018-09-01
|
Series: | Translation |
Online Access: | https://openjournals.utoledo.edu/index.php/translation/article/view/243 |
Similar Items
-
Specific inhibitors of urokinase plasminogen activator for treatment of cancers; In silico approach
by: Benjamin Talbot, et al.
Published: (2020-05-01) -
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer
by: Lim Kyu, et al.
Published: (2006-08-01) -
TISSUE INHIBITOR OF METALLOPROTEINASE 1, MATRIX METALLOPROTEINASE 9, ALPHA-1 ANTITRYPSIN, METALLOTHIONEIN AND UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN SKIN BIOPSIES FROM PATIENTS AFFECTED BY AUTOIMMUNE BLISTERING DISEASES
by: Ana Maria Abreu Velez, et al.
Published: (2013-07-01) -
Designing novel quercetin derivatives as matrix metalloproteinase-9 inhibitors in colon carcinoma: An In vitro and in silico approach
by: Sangeeta Ballav, et al.
Published: (2020-01-01) -
Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator
by: Chongjun Shi, et al.
Published: (2017-03-01)